394 related articles for article (PubMed ID: 24516024)
1. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.
Moxon-Emre I; Bouffet E; Taylor MD; Laperriere N; Scantlebury N; Law N; Spiegler BJ; Malkin D; Janzen L; Mabbott D
J Clin Oncol; 2014 Jun; 32(17):1760-8. PubMed ID: 24516024
[TBL] [Abstract][Full Text] [Related]
2. Intellectual Outcome in Molecular Subgroups of Medulloblastoma.
Moxon-Emre I; Taylor MD; Bouffet E; Hardy K; Campen CJ; Malkin D; Hawkins C; Laperriere N; Ramaswamy V; Bartels U; Scantlebury N; Janzen L; Law N; Walsh KS; Mabbott DJ
J Clin Oncol; 2016 Dec; 34(34):4161-4170. PubMed ID: 27507873
[TBL] [Abstract][Full Text] [Related]
3. Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma.
Moxon-Emre I; Bouffet E; Taylor MD; Laperriere N; Sharpe MB; Laughlin S; Bartels U; Scantlebury N; Law N; Malkin D; Skocic J; Richard L; Mabbott DJ
J Neurosurg Pediatr; 2016 Jul; 18(1):29-40. PubMed ID: 27015518
[TBL] [Abstract][Full Text] [Related]
4. Late toxicity following craniospinal radiation for early-stage medulloblastoma.
Christopherson KM; Rotondo RL; Bradley JA; Pincus DW; Wynn TT; Fort JA; Morris CG; Mendenhall NP; Marcus RB; Indelicato DJ
Acta Oncol; 2014 Apr; 53(4):471-80. PubMed ID: 24564687
[TBL] [Abstract][Full Text] [Related]
5. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma.
Kahalley LS; Peterson R; Ris MD; Janzen L; Okcu MF; Grosshans DR; Ramaswamy V; Paulino AC; Hodgson D; Mahajan A; Tsang DS; Laperriere N; Whitehead WE; Dauser RC; Taylor MD; Conklin HM; Chintagumpala M; Bouffet E; Mabbott D
J Clin Oncol; 2020 Feb; 38(5):454-461. PubMed ID: 31774710
[TBL] [Abstract][Full Text] [Related]
6. Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma.
Palmer SL; Gajjar A; Reddick WE; Glass JO; Kun LE; Wu S; Xiong X; Mulhern RK
Neuropsychology; 2003 Oct; 17(4):548-55. PubMed ID: 14599268
[TBL] [Abstract][Full Text] [Related]
7. Critical combinations of radiation dose and volume predict intelligence quotient and academic achievement scores after craniospinal irradiation in children with medulloblastoma.
Merchant TE; Schreiber JE; Wu S; Lukose R; Xiong X; Gajjar A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):554-61. PubMed ID: 25160611
[TBL] [Abstract][Full Text] [Related]
8. Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma.
Tian S; Sudmeier LJ; Zhang C; Madden NA; Buchwald ZS; Shu HG; Curran WJ; Eaton BR; Esiashvili N
Pediatr Blood Cancer; 2020 Jan; 67(1):e28027. PubMed ID: 31571408
[TBL] [Abstract][Full Text] [Related]
9. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
[TBL] [Abstract][Full Text] [Related]
10. Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy.
Câmara-Costa H; Resch A; Kieffer V; Lalande C; Poggi G; Kennedy C; Bull K; Calaminus G; Grill J; Doz F; Rutkowski S; Massimino M; Kortmann RD; Lannering B; Dellatolas G; Chevignard M;
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):978-985. PubMed ID: 26194675
[TBL] [Abstract][Full Text] [Related]
11. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.
Ris MD; Packer R; Goldwein J; Jones-Wallace D; Boyett JM
J Clin Oncol; 2001 Aug; 19(15):3470-6. PubMed ID: 11481352
[TBL] [Abstract][Full Text] [Related]
12. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
13. Trifecta of science: originality, controversy, confirmation.
Ris MD
J Clin Oncol; 2014 Jun; 32(17):1749-50. PubMed ID: 24778398
[No Abstract] [Full Text] [Related]
14. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses.
Sethi RV; Giantsoudi D; Raiford M; Malhi I; Niemierko A; Rapalino O; Caruso P; Yock TI; Tarbell NJ; Paganetti H; MacDonald SM
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):655-63. PubMed ID: 24521681
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK; Palmer SL; Merchant TE; Wallace D; Kocak M; Brouwers P; Krull K; Chintagumpala M; Stargatt R; Ashley DM; Tyc VL; Kun L; Boyett J; Gajjar A
J Clin Oncol; 2005 Aug; 23(24):5511-9. PubMed ID: 16110011
[TBL] [Abstract][Full Text] [Related]
16. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
17. Local control in non-metastatic medulloblastoma.
Christopherson KM; Bradley JA; Rotondo RL; Pincus DW; Fort JA; Morris CG; Mendenhall NP; Marcus RB; Indelicato DJ
Acta Oncol; 2014 Sep; 53(9):1151-7. PubMed ID: 24991891
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study.
Mulhern RK; Kepner JL; Thomas PR; Armstrong FD; Friedman HS; Kun LE
J Clin Oncol; 1998 May; 16(5):1723-8. PubMed ID: 9586884
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.
Douglas JG; Barker JL; Ellenbogen RG; Geyer JR
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1161-4. PubMed ID: 15001259
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of conformal radiation therapy for medulloblastoma.
Merchant TE; Happersett L; Finlay JL; Leibel SA
Neuro Oncol; 1999 Jul; 1(3):177-87. PubMed ID: 11550312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
